Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer

Background: Pembrolizumab is a guideline-recommended, both first- and second-line treatment option for microsatellite-instability-high (MSI-H)/mismatch repair-deficient (dMMR)advanced colorectal cancer patients. The aim of the present study is to investigates the health and economic outcomes of thre...

Full description

Bibliographic Details
Main Authors: Tan Chongqing, Li Sini, Zeng Xiaohui, Peng Liubao, Peng Ye, Qin Shuxia, Wang Liting, Wu Meiyu, Wan Xiaomin
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Pharmacology
Subjects:
pembrolizumab
colorectal neoplasms
immunotherapy
cost-effectiveness
microsatellite-instability-high/mismatch repair-deficient
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.802942/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.802942/full

Similar Items